{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T12:46:46Z","timestamp":1791636406250,"version":"4.3.4"},"reference-count":59,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"Pfizer Inc. Ahuva Averin, Erin Quinn, and Mark Atwood are employees of Avalere Health"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines &amp; Immunotherapeutics"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/21645515.2025.2521912","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T14:01:12Z","timestamp":1750860072000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["Cost-effectiveness of immunization strategies to protect infants against respiratory syncytial virus in the Netherlands"],"prefix":"10.1080","volume":"21","author":[{"given":"Annefleur C.","family":"Langedijk","sequence":"first","affiliation":[{"name":"Pfizer B.V","place":["Capelle aan den IJssel, the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floris","family":"van den Dungen","sequence":"additional","affiliation":[{"name":"Pfizer B.V","place":["Capelle aan den IJssel, the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette","family":"Harteveld","sequence":"additional","affiliation":[{"name":"Spaarne Gasthuis Hospital","place":["Haarlem, the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie","family":"van den Boer","sequence":"additional","affiliation":[{"name":"Midwives Amsterdam Zuid","place":["Amsterdam, the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Smit","sequence":"additional","affiliation":[{"name":"Jeugdgezondheidszorg Kennemerland","place":["Velserbroek, the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahuva","family":"Averin","sequence":"additional","affiliation":[{"name":"Avalere Health","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Quinn","sequence":"additional","affiliation":[{"name":"Avalere Health","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Atwood","sequence":"additional","affiliation":[{"name":"Avalere Health","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Law","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Mendes","sequence":"additional","affiliation":[{"name":"Pfizer Ltd","place":["Tadworth, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"van Houten","sequence":"additional","affiliation":[{"name":"Spaarne Gasthuis Hospital","place":["Haarlem, the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"e_1_3_5_2_1","unstructured":"National Institute for Public Health and the Environment: Ministry of Health WaS. Respiratory syncytial virus (RSV). 2024. https:\/\/www.rivm.nl\/en\/rsv#:~:text=RSV%20is%20common%20in%20the%20Netherlands %20especially%20in."},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00414-3"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00478-0"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac150"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.01.058"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(22)00321-2"},{"key":"e_1_3_5_8_1","volume-title":"Paper presented at: RSVVW\u201924","author":"Munjal I","year":"2024","unstructured":"Munjal I, Pahud BA, Sim\u00f5es EAF. Prevention of infant RSV illness with a bivalent RSV prefusion F vaccine administered during pregnancy: efficacy results from a phase 3 global clinical trial. Paper presented at: RSVVW\u201924; 2024 Feb 13\u201316; Mumbai, India."},{"key":"e_1_3_5_9_1","unstructured":"European Medicines Agency. Beyfortus. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/beyfortus."},{"key":"e_1_3_5_10_1","unstructured":"European Medicines Agency. Abrysvo. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/abrysvo."},{"key":"e_1_3_5_11_1","unstructured":"Health Council of the Netherlands. Immunisation against RSV in the first year of life. 2024. https:\/\/www.healthcouncil.nl\/documents\/advisory-reports\/2024\/02\/14\/immunisation-against-rsv-in-the-first-year-of-life."},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126541"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2216480"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2023.100629"},{"key":"e_1_3_5_15_1","unstructured":"Statistics Netherlands. Consumer price index 2015 = 100. 2024. https:\/\/opendata.cbs.nl\/#\/CBS\/nl\/dataset\/83131NED\/table."},{"key":"e_1_3_5_16_1","unstructured":"Perined. Peristat.nl. 2022. https:\/\/www.peristat.nl\/."},{"key":"e_1_3_5_17_1","unstructured":"Central Bureau of Statistics. Population development; month and year. 2024. https:\/\/opendata.cbs.nl\/statline\/#\/CBS\/nl\/dataset\/83474NED\/table?ts=1696324589494."},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2019.02.012"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00367-9"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piz011"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.10.023"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae544"},{"key":"e_1_3_5_23_1","unstructured":"National Institute for Public Health and the Environment: Ministry of Health Welfare and Sport. State of affairs RS virus. 2024. https:\/\/www.rivm.nl\/rs-virus\/stand-van-zaken-rs-virus."},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-3611"},{"key":"e_1_3_5_25_1","unstructured":"Central Bureau of Statistics. Mortality; key figures. 2023. https:\/\/www.cbs.nl\/nl-nl\/cijfers\/detail\/37979eng#DeathsUnder4Weeks_6."},{"key":"e_1_3_5_26_1","unstructured":"Office for National Statistics. Child mortality (death cohort) tables in England and Wales. 2019. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths\/datasets\/childmortalitystatisticschildhoodinfantandperinatalchildhoodinfantandperinatalmortalityinenglandandwales."},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100829"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000005816"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7309a4"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187477"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-021-04079-y"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100965"},{"key":"e_1_3_5_33_1","unstructured":"Netherlands Youth Institute. Figures on working parents. 2024. https:\/\/www.nji.nl\/cijfers\/werkende-ouders#arbeidsdeelname-van-ouders."},{"key":"e_1_3_5_34_1","unstructured":"Central Bureau of Statistics. Hourly wage. 2024. https:\/\/www.cbs.nl\/nl-nl\/visualisaties\/dashboard-arbeidsmarkt\/ontwikkeling-cao-lonen\/uurloon."},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad598"},{"key":"e_1_3_5_36_1","unstructured":"Trading Economics. Netherlands: employment rate. 2024. https:\/\/tradingeconomics.com\/netherlands\/employment-rate-females-eurostat-data.html#:~:text=Netherlands%20%2D%20Employment%20rate%3A%20Females%20was EUROSTAT%20on%20November%20of%202023."},{"key":"e_1_3_5_37_1","unstructured":"Central Bureau of Statistics. Deaths; cause of death (extensive list) age and sex. 2024. https:\/\/opendata.cbs.nl\/statline\/#\/CBS\/en\/dataset\/7233ENG\/table?ts=1737039393756."},{"key":"e_1_3_5_38_1","unstructured":"Netherlands National Health Care Institute. Guideline for economic evaluations in healthcare (2024 version). 2024. https:\/\/english.zorginstituutnederland.nl\/site\/binaries\/site-content\/collections\/documents\/2024\/01\/16\/guideline-for-economic-evaluations-in-healthcare\/Guideline+for+economic+evaluations+in+healthcare.pdf."},{"key":"e_1_3_5_39_1","unstructured":"G-standaard Taxe. 2024 Nov."},{"key":"e_1_3_5_40_1","unstructured":"Belgian Centre for Pharmacotherapeutic Information. Commented directory of medicines: nirsevimab. 2024. https:\/\/www.cbip.be\/fr\/chapters\/12?frag=8905127&trade_family=48348."},{"key":"e_1_3_5_41_1","unstructured":"Norwegian Directorate for Medical Products. Drug display: Beyfortus. 2024. https:\/\/www.legemiddelsok.no\/sider\/Legemiddelvisning.aspx?pakningId=6b14f7e8-9a5b-4a0d-be46-fdc9a6f7b9ab&searchquery=Beyfortus&f=Han;MtI;Vir;ATC;Var;Ikk;Mar;Mid;Avr;gen;par;&pane=0."},{"key":"e_1_3_5_42_1","unstructured":"French Republic. Notice relating to the prices of proprietary medicinal products. 2024. https:\/\/www.legifrance.gouv.fr\/jorf\/id\/JORFTEXT000049487117?init=true&page=1&query=beyfortus&searchField=ALL&tab_selection=all."},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101141"},{"key":"e_1_3_5_44_1","unstructured":"Roy LMC. Deriving health utility weights for infants with Respiratory Syncytial Virus (RSV). 2013. https:\/\/open.library.ubc.ca\/soa\/cIRcle\/collections\/ubctheses\/24\/items\/1.0074259."},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12686"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.01.003"},{"key":"e_1_3_5_47_1","volume-title":"Paper presented at: meeting of the ACIP","author":"Hutton D","year":"2023","unstructured":"Hutton D. Economic analysis of nirsevimab in pediatric populations. Paper presented at: meeting of the ACIP; 2023 Feb 23; Atlanta, GA."},{"key":"e_1_3_5_48_1","unstructured":"Dutch National Healthcare Institute. Guideline for economic evaluations in healthcare (2024 version). 2024. https:\/\/english.zorginstituutnederland.nl\/site\/binaries\/site-content\/collections\/documents\/2024\/01\/16\/guideline-for-economic-evaluations-in-healthcare\/Guideline+for+economic+evaluations+in+healthcare.pdf."},{"key":"e_1_3_5_49_1","unstructured":"National Institute for Public Health and the Environment: Ministry of Health Welfare and Sport. The national immunisation programme in the Netherlands: Surveillance and developments in 2021-2022. 2022. [accessed 2020 Nov]."},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6840e1"},{"key":"e_1_3_5_51_1","article-title":"Vaccination coverage and annual report of the National Immunisation programme in the Netherlands, 2022","author":"van Lier EA","year":"2023","unstructured":"van Lier EA, Hament JM, Knijff M, Westra M, Ernst A, Giesbers H. Vaccination coverage and annual report of the National Immunisation programme in the Netherlands, 2022. Rijksinstituut voor Volksgezondheid en Milieu RIVM; 2023.http:\/\/hdl.handle.net\/10029\/626797.","journal-title":"Rijksinstituut voor Volksgezondheid en Milieu RIVM"},{"key":"e_1_3_5_52_1","volume-title":"Paper presented at: vaccinology masterclass: the NIP in motion","author":"Hament J-M","year":"2024","unstructured":"Hament J-M. Challenges in the implementation of RSV immunization. Paper presented at: vaccinology masterclass: the NIP in motion; 2024 Dec; Almere, the Netherlands."},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309189"},{"key":"e_1_3_5_54_1","volume-title":"Presentation at the World Vaccine Congress","author":"Munjal IA","year":"2024","unstructured":"Munjal IA. Bivalent RSVpreF vaccine to protect against infant illness through immunization of pregnant individuals and older adults via direct immunization. Presentation at the World Vaccine Congress; 2024 Apr 1\u20134; Washington, DC."},{"key":"e_1_3_5_55_1","volume-title":"Paper presented at: RSVVW\u201924","author":"Munjal I","year":"2024","unstructured":"Munjal I. Protection against infant illness with abivalent RSVpreF vaccine in pregnancy: final analysis. Paper presented at: RSVVW\u201924; 2024; Mumbai, India."},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2022-009693"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.advnut.2024.100218"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7107e3"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01282"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001981"}],"container-title":["Human Vaccines &amp; Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2025.2521912","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/21645515.2025.2521912","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2025.2521912","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:45:08Z","timestamp":1786034708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2025.2521912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/21645515.2025.2521912"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2025.2521912","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-03-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2521912"}}